Q32 Bio (QTTB) Liabilities and Shareholders Equity (2017 - 2026)

Q32 Bio has reported Liabilities and Shareholders Equity for 10 years, with the latest figure at $63.7 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 19.47% year-over-year to $63.7 million; the trailing twelve-month figure through Mar 2026 stood at $249.4 million (down 37.69% YoY), and the FY2025 full-year result was $61.8 million, down 33.09% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $63.7 million, up from $61.8 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $311.0 million in Q1 2022, with the low at $47.1 million in Q4 2023.
• Average Liabilities and Shareholders Equity over 5 years is $143.7 million, with a median of $124.2 million recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity sank 79.4% in 2023 and jumped 96.21% in 2024.
• Tracing QTTB's Liabilities and Shareholders Equity over 5 years: stood at $228.5 million in 2022, then slumped by 79.4% to $47.1 million in 2023, then soared by 96.21% to $92.3 million in 2024, then slumped by 33.09% to $61.8 million in 2025, then grew by 3.07% to $63.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $63.7 million (Q1 2026), $61.8 million (Q4 2025), and $57.8 million (Q3 2025), per Business Quant data.

Peer Comparison